Bausch Health Companies (BHC) Income from Non-Controlling Interests (2013 - 2026)
Bausch Health Companies' (BHC) quarterly Income from Non-Controlling Interests came in at $2.0 million in Q2 2026, up 110.0% year-over-year from $952381.0 in Q2 2025, and up 125.0% quarter-over-quarter from -$8.0 million in Q1 2026.
Analysis
Bausch Health Companies (BHC) Income from Non-Controlling Interests (2013 - 2026) Analysis & Trends
Bausch Health Companies has disclosed Income from Non-Controlling Interests across 14 years of filings, most recently posting $2.0 million for Q2 2026.
- In Q2 2026, Income from Non-Controlling Interests rose 110.0% year-over-year to $2.0 million; the TTM figure through Jun 2026 stood at $5.0 million (up 110.0% YoY), while the FY2025 annual figure was -$37.0 million, down 42.31% from the prior year.
- Income from Non-Controlling Interests came in at $2.0 million for Q2 2026 at Bausch Health Companies, up from -$8.0 million in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of $9.0 million in Q4 2025 to a low of -$28.0 million in Q1 2025.
- Average Income from Non-Controlling Interests over 5 years is -$4.4 million, with a median of -$4.0 million recorded in 2023.
- Year-over-year, Income from Non-Controlling Interests soared 200.0% in 2022 and sank 1200.0% in 2024.
- Over 5 years, Income from Non-Controlling Interests stood at $4.0 million in 2022, then plunged by 300.0% to -$8.0 million in 2023, then surged by 162.5% to $5.0 million in 2024, then jumped by 80.0% to $9.0 million in 2025, then sank by 77.78% to $2.0 million in 2026.
- Per Business Quant data, the three most recent Income from Non-Controlling Interests figures were $2.0 million in Q2 2026, -$8.0 million in Q1 2026, and $9.0 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.84 Bn | 39.19 Bn | 2.15 Bn | - |
| 2 | Viatris | 19.13 Bn | 18.24 Bn | 1.46 Bn | - |
| 3 | Dr Reddys Laboratories | 9.91 Bn | 9.74 Bn | 396.53 Mn | -918,959.97 |
| 4 | Amneal Pharmaceuticals | 5.51 Bn | 5.38 Bn | 334.51 Mn | 11.95 Mn |
| 5 | Bausch Health Companies | 2.30 Bn | 464.50 Mn | 2.10 Bn | 2.00 Mn |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn | - |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn | - |
| 8 | Amphastar Pharmaceuticals | 1.00 Bn | 714.13 Mn | 93.47 Mn | - |
| 9 | Fennec Pharmaceuticals | 402.10 Mn | 360.85 Mn | 17.15 Mn | - |
| 10 | RedHill Biopharma | 178.35 Mn | 178.35 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.00 Mn |
| Mar 31, 2026 | -8.00 Mn |
| Dec 31, 2025 | 9.00 Mn |
| Sep 30, 2025 | 2.00 Mn |
| Jun 30, 2025 | -20.00 Mn |
| Mar 31, 2025 | -28.00 Mn |
| Dec 31, 2024 | 5.00 Mn |
| Sep 30, 2024 | -7.00 Mn |
| Jun 30, 2024 | -11.00 Mn |
| Mar 31, 2024 | -13.00 Mn |
| Dec 31, 2023 | -8.00 Mn |
| Sep 30, 2023 | -4.00 Mn |
| Jun 30, 2023 | 1.00 Mn |
| Mar 31, 2023 | -8.00 Mn |
| Sep 30, 2022 | 4.00 Mn |
| Jun 30, 2022 | 6.00 Mn |
| Mar 31, 2022 | 3.00 Mn |
| Dec 31, 2021 | 3.00 Mn |
| Sep 30, 2021 | 3.00 Mn |
| Jun 30, 2021 | 2.00 Mn |